Disc Medicine to Host Webcast on APOLLO Phase 3 Results for Bitopertin in EPP

• Disc Medicine will host a corporate webcast on October 19, 2026, at 8 a.m. ET.
• The webcast will discuss topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610181700PRIMZONEFULLFEED9847972) on October 18, 2026, and is solely responsible for the information contained therein.